David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Emerson Electric
EMR
|
+$546M |
| 2 |
Amazon
AMZN
|
+$515M |
| 3 |
Tesla
TSLA
|
+$389M |
| 4 |
Netflix
NFLX
|
+$322M |
| 5 |
Adobe
ADBE
|
+$305M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$836M |
| 2 |
CELG
Celgene Corp
CELG
|
+$460M |
| 3 |
NVIDIA
NVDA
|
+$429M |
| 4 |
ConocoPhillips
COP
|
+$311M |
| 5 |
Biogen
BIIB
|
+$301M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.8% |
| 2 | Consumer Discretionary | 11.76% |
| 3 | Healthcare | 10.16% |
| 4 | Financials | 7.89% |
| 5 | Industrials | 6.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Regis Corp
RGS
$67M
| $4.29M | ﹤0.01% |
12,008
-6,896
| -36% | -$2.56M |
|
|
EGRX
1802
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $4.29M | ﹤0.01% |
71,392
-16,384
| -19% | -$977K |
|
1803
PUT
Nucor
NUE
$57.4B
| $4.28M | ﹤0.01% |
76,100
+48,000
| +171% | +$2.62M |
|
1804
Hilton Grand Vacations
HGV
$3.5B
| $4.28M | ﹤0.01% |
+124,423
| New | +$4.28M |
|
|
KBAL
1805
DELISTED
Kimball International
KBAL
| $4.28M | ﹤0.01% |
206,780
-11,585
| -5% | -$239K |
|
1806
Stellantis
STLA
$19.4B
| $4.27M | ﹤0.01% |
290,883
-559,765
| -66% | -$8.09M |
|
1807
Peabody Energy
BTU
$3.33B
| $4.26M | ﹤0.01% |
466,986
-106,914
| -19% | -$1.23M |
|
1808
Dorian LPG
LPG
$2.05B
| $4.25M | ﹤0.01% |
274,439
+170,925
| +165% | +$2.25M |
|
1809
UMB Financial
UMBF
$10.9B
| $4.24M | ﹤0.01% |
61,706
+4,009
| +7% | +$266K |
|
|
SAND
1810
DELISTED
Sandstorm Gold
SAND
| $4.22M | ﹤0.01% |
566,242
-3,221
| -0.6% | -$21K |
|
1811
CALL
Clorox
CLX
$12.6B
| $4.22M | ﹤0.01% |
27,500
| – | – |
|
1812
HEICO Corp
HEI
$48.4B
| $4.22M | ﹤0.01% |
36,983
-31,645
| -46% | -$3.89M |
|
1813
Acadia Healthcare
ACHC
$2.85B
| $4.22M | ﹤0.01% |
+127,024
| New | +$3.98M |
|
1814
PUT
SL Green Realty
SLG
$4.16B
| $4.22M | ﹤0.01% |
47,415
| – | – |
|
1815
PPG Industries
PPG
$25.4B
| $4.21M | ﹤0.01% |
31,551
+4,162
| +15% | +$527K |
|
|
TSE
1816
DELISTED
Trinseo
TSE
| $4.21M | ﹤0.01% |
113,043
-32,606
| -22% | -$1.32M |
|
1817
Standard BioTools
LAB
$256M
| $4.2M | ﹤0.01% |
1,207,185
+119,310
| +11% | +$420K |
|
1818
Lands' End
LE
$374M
| $4.2M | ﹤0.01% |
249,714
+85,660
| +52% | +$1.12M |
|
1819
TriMas Corp
TRS
$1.44B
| $4.19M | ﹤0.01% |
133,356
-17,110
| -11% | -$528K |
|
1820
Cenovus Energy
CVE
$58.1B
| $4.17M | ﹤0.01% |
410,198
-1,795,951
| -81% | -$16.3M |
|
1821
EPR Properties
EPR
$4.6B
| $4.17M | ﹤0.01% |
+58,970
| New | +$4.35M |
|
1822
State Street SPDR S&P Biotech ETF
XBI
$11.7B
| $4.16M | ﹤0.01% |
43,690
| – | – |
|
1823
Skyworks Solutions
SWKS
$10B
| $4.15M | ﹤0.01% |
34,347
+8,497
| +33% | +$835K |
|
1824
Wabash National
WNC
$510M
| $4.15M | ﹤0.01% |
282,622
-31,030
| -10% | -$461K |
|
|
BNFT
1825
DELISTED
Benefitfocus, Inc.
BNFT
| $4.15M | ﹤0.01% |
189,096
-14,569
| -7% | -$330K |
|
Similar funds
David Shaw's Q4 2019 Portfolio in Review
As of Q4 2019, David Shaw held 4,337 positions worth $87.5B, up 7.7% from $81.2B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
David Shaw's Q4 2019 filing shows 572 new, 1,477 increased, 1,498 reduced and 412 closed positions. Its largest new stake was Tesla: 17,953,230 shares worth $501M. The largest sale was Alibaba, an estimated $836M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- David Shaw's largest Q4 2019 buy was Tesla: 17,953,230 shares worth $501M.
- David Shaw added most to Emerson Electric in Q4 2019, an estimated $546M increase.
- David Shaw's biggest Q4 2019 reduction was Alibaba, cutting an estimated $836M.
- David Shaw fully exited Celgene Corp in Q4 2019, selling an estimated $460M.
- David Shaw's ten largest holdings make up 10% of its $87.5B portfolio in Q4 2019.
- David Shaw opened 572 new positions and closed 412 in Q4 2019.
- David Shaw's portfolio value rose 7.7% quarter-over-quarter to $87.5B.
Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.